$268 Million is the total value of Endurant Capital Management LP's 69 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AGN | Buy | ALLERGAN PLC | $17,231,000 | +37.7% | 102,391 | +33.9% | 6.44% | +68.3% |
ABT | Buy | ABBOTT LABS | $16,582,000 | +102.6% | 276,732 | +93.0% | 6.19% | +147.7% |
JNJ | Buy | JOHNSON & JOHNSON | $14,623,000 | +72.1% | 114,111 | +87.7% | 5.46% | +110.3% |
MDT | Buy | MEDTRONIC PLC | $10,839,000 | +15.4% | 135,115 | +16.2% | 4.05% | +41.0% |
BDX | Buy | BECTON DICKINSON & CO | $10,625,000 | +147.3% | 49,030 | +144.3% | 3.97% | +202.3% |
BSX | Buy | BOSTON SCIENTIFIC CORP | $10,592,000 | +24.7% | 387,698 | +13.2% | 3.96% | +52.4% |
UHS | New | UNIVERSAL HLTH SVCS INCcl b | $9,875,000 | – | 83,400 | +100.0% | 3.69% | – |
UNH | Buy | UNITEDHEALTH GROUP INC | $9,717,000 | +14.0% | 45,408 | +17.5% | 3.63% | +39.3% |
ANTM | Buy | ANTHEM INC | $9,690,000 | +91.3% | 44,105 | +95.9% | 3.62% | +133.9% |
MRK | Buy | MERCK & CO INC | $9,407,000 | +57.6% | 172,700 | +62.8% | 3.51% | +92.5% |
SHPG | Buy | SHIRE PLCsponsored adr | $8,066,000 | +59.0% | 53,996 | +65.1% | 3.01% | +94.4% |
SYNH | New | SYNEOS HEALTH INCcl a | $6,830,000 | – | 192,400 | +100.0% | 2.55% | – |
CVS | Buy | CVS HEALTH CORP | $6,477,000 | +67.6% | 104,111 | +95.3% | 2.42% | +104.8% |
MYL | Buy | MYLAN N V | $6,443,000 | +28.1% | 156,487 | +31.6% | 2.41% | +56.6% |
LH | Buy | LABORATORY CORP AMER HLDGS | $4,784,000 | +45.8% | 29,575 | +43.7% | 1.79% | +78.2% |
HCA | New | HCA HEALTHCARE INC | $4,346,000 | – | 44,800 | +100.0% | 1.62% | – |
GILD | New | GILEAD SCIENCES INC | $3,558,000 | – | 47,200 | +100.0% | 1.33% | – |
CI | Buy | CIGNA CORPORATION | $3,455,000 | +751.0% | 20,600 | +930.0% | 1.29% | +941.1% |
MASI | New | MASIMO CORP | $1,838,000 | – | 20,900 | +100.0% | 0.69% | – |
INCY | Buy | INCYTE CORP | $1,618,000 | +130.2% | 19,420 | +161.7% | 0.60% | +180.9% |
PPH | New | VANECK VECTORS ETF TRpharmaceutical | $1,449,000 | – | 25,500 | +100.0% | 0.54% | – |
PKI | Buy | PERKINELMER INC | $1,442,000 | +109.6% | 19,041 | +102.5% | 0.54% | +156.7% |
VRX | New | VALEANT PHARMACEUTICALS INTL | $1,356,000 | – | 85,200 | +100.0% | 0.51% | – |
A | New | AGILENT TECHNOLOGIES INC | $1,338,000 | – | 20,000 | +100.0% | 0.50% | – |
DGX | New | QUEST DIAGNOSTICS INC | $1,304,000 | – | 13,000 | +100.0% | 0.49% | – |
ARRY | Buy | ARRAY BIOPHARMA INC | $1,165,000 | +79.8% | 71,400 | +41.1% | 0.44% | +119.7% |
OCUL | New | OCULAR THERAPEUTIX INC | $1,162,000 | – | 178,461 | +100.0% | 0.43% | – |
ICLR | New | ICON PLC | $992,000 | – | 8,400 | +100.0% | 0.37% | – |
BLCM | New | BELLICUM PHARMACEUTICALS INC | $947,000 | – | 144,300 | +100.0% | 0.35% | – |
TFX | New | TELEFLEX INC | $918,000 | – | 3,600 | +100.0% | 0.34% | – |
JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $770,000 | +15.4% | 5,100 | +3.0% | 0.29% | +41.2% |
XRAY | New | DENTSPLY SIRONA INC | $664,000 | – | 13,200 | +100.0% | 0.25% | – |
QGEN | New | QIAGEN NV | $662,000 | – | 20,500 | +100.0% | 0.25% | – |
VKTX | New | VIKING THERAPEUTICS INC | $520,000 | – | 119,100 | +100.0% | 0.19% | – |
RETA | New | REATA PHARMACEUTICALS INCcl a | $513,000 | – | 25,000 | +100.0% | 0.19% | – |
AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $406,000 | – | 55,700 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
MCKESSON CORP | 27 | Q1 2023 | 4.4% |
CENCORA INC | 26 | Q3 2023 | 5.9% |
HOLOGIC INC | 24 | Q3 2023 | 7.5% |
JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-07 |
SC 13D/A | 2024-04-10 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13D/A | 2023-09-08 |
13F-HR | 2023-08-14 |
3/A | 2023-05-24 |
13F-HR | 2023-05-15 |
3 | 2023-05-15 |
SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.